Cancer - New-wiki

Novel	Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
Novel Novel	Symbols SNCA and LIN7C	Name 1 synuclein alpha	Name2 lin-7 cell polarity scaffold C	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Dopamine Neurotransmitter Release Cycle Neurexins and neuroligins Assembly and cell surface presentation of NMDA receptors	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel Novel	Symbols SNCA and LRFN2	Name 1 synuclein alpha	Name2 leucine rich repeat and fibronectin type III domain containing 2	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Synaptic adhesion-like molecules	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel Novel	Symbols SNCA and OSBPL7	Name 1 synuclein alpha	Name2 oxysterol binding protein like 7	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Synthesis of bile acids and bile salts	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel Novel	Symbols SNCA and PSD3	Name 1 synuclein alpha	Name2 pleckstrin and Sec7 domain containing 3	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel Novel	Symbols SNCA and RUFY1	Name 1 synuclein alpha	Name2 RUN and FYVE domain containing 1	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Synthesis of PIPs at the plasma membrane	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel Novel	Symbols SNCA and SNX16	Name 1 synuclein alpha	Name2 sorting nexin 16	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel Novel	Symbols SNCA and TRPV6	Name 1 synuclein alpha	Name2 transient receptor potential cation channel subfamily V member 6	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 TRP channels	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel Novel	Symbols SNCA and TH	Name 1 synuclein alpha	Name2 tyrosine hydroxylase	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Catecholamine biosynthesis	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2 Phenylalanine Tyrosine Sapropterin Metyrosine 3-Tyrosine L-erythro-7,8-dihydrobiopterin	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2 Primary torsion dystonia (PTD)
Novel Novel	Symbols EPB41L1 and STARD13	Name 1 erythrocyte membrane protein band 4.1 like 1	Name2 StAR related lipid transfer domain containing 13	Pathway 1 Trafficking of AMPA receptors Neurexins and neuroligins Sensory processing of sound by inner hair cells of the cochlea Sensory processing of sound by outer hair cells of the cochlea	Pathway 2 RHOA GTPase cycle RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols EPB41L1 and GRIA1	Name 1 erythrocyte membrane protein band 4.1 like 1	Name2 glutamate ionotropic receptor AMPA type subunit 1	Pathway 1 Trafficking of AMPA receptors Neurexins and neuroligins Sensory processing of sound by inner hair cells of the cochlea Sensory processing of sound by outer hair cells of the cochlea	Pathway 2 COPII-mediated vesicle transport Activation of AMPA receptors Trafficking of AMPA receptors Trafficking of GluR2-containing AMPA receptors Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Cargo concentration in the ER Synaptic adhesion-like molecules Long-term potentiation	Drugs 1	Drugs 2 Glutamic acid Butabarbital Lamotrigine Isoflurane Ethanol Methoxyflurane Desflurane Sevoflurane Talampanel CX-717 CX516 Perampanel Tianeptine Fluciclovine (18F)	Diseases 1	Diseases 2
Novel Novel	Symbols RELA and UNC5CL	Name 1 RELA proto-oncogene, NF-kB subunit	Name2 unc-5 family C-terminal like	Pathway 1 Activation of NF-kappaB in B cells RIP-mediated NFkB activation via ZBP1 Regulated proteolysis of p75NTR Downstream TCR signaling NF-kB is activated and signals survival Senescence-Associated Secretory Phenotype (SASP) FCERI mediated NF-kB activation DEx/H-box helicases activate type I IFN and inflammatory cytokines production PKMTs methylate histone lysines Transcriptional regulation of white adipocyte differentiation TAK1-dependent IKK and NF-kappa-B activation Interleukin-1 processing SUMOylation of immune response proteins IkBA variant leads to EDA-ID Dectin-1 mediated noncanonical NF-kB signaling CLEC7A (Dectin-1) signaling CD209 (DC-SIGN) signaling CLEC7A/inflammasome pathway The NLRP3 inflammasome Transcriptional Regulation by VENTX Interleukin-1 signaling TRAF6 mediated NF-kB activation Purinergic signaling in leishmaniasis infection SARS-CoV-1 activates/modulates innate immune responses Regulation of NFE2L2 gene expression Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells Regulation of PD-L1(CD274) transcription	Pathway 2	Drugs 1 Glucosamine Dimethyl fumarate SC-236	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols RELA and UBE2C	Name 1 RELA proto-oncogene, NF-kB subunit	Name2 ubiquitin conjugating enzyme E2 C	Pathway 1 Activation of NF-kappaB in B cells RIP-mediated NFkB activation via ZBP1 Regulated proteolysis of p75NTR Downstream TCR signaling NF-kB is activated and signals survival Senescence-Associated Secretory Phenotype (SASP) FCERI mediated NF-kB activation DEx/H-box helicases activate type I IFN and inflammatory cytokines production PKMTs methylate histone lysines Transcriptional regulation of white adipocyte differentiation TAK1-dependent IKK and NF-kappa-B activation Interleukin-1 processing SUMOylation of immune response proteins IkBA variant leads to EDA-ID Dectin-1 mediated noncanonical NF-kB signaling CLEC7A (Dectin-1) signaling CD209 (DC-SIGN) signaling CLEC7A/inflammasome pathway The NLRP3 inflammasome Transcriptional Regulation by VENTX Interleukin-1 signaling TRAF6 mediated NF-kB activation Purinergic signaling in leishmaniasis infection SARS-CoV-1 activates/modulates innate immune responses Regulation of NFE2L2 gene expression Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells Regulation of PD-L1(CD274) transcription	Pathway 2 Inactivation of APC/C via direct inhibition of the APC/C complex APC/C:Cdc20 mediated degradation of Cyclin B Autodegradation of Cdh1 by Cdh1:APC/C APC/C:Cdc20 mediated degradation of Securin APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 Cdc20:Phospho-APC/C mediated degradation of Cyclin A Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase Regulation of APC/C activators between G1/S and early anaphase APC/C:Cdc20 mediated degradation of mitotic proteins Phosphorylation of the APC/C APC-Cdc20 mediated degradation of Nek2A Separation of Sister Chromatids Senescence-Associated Secretory Phenotype (SASP) Assembly of the pre-replicative complex CDK-mediated phosphorylation and removal of Cdc6 Transcriptional Regulation by VENTX Synthesis of active ubiquitin: roles of E1 and E2 enzymes Aberrant regulation of mitotic exit in cancer due to RB1 defects Antigen processing: Ubiquitination & Proteasome degradation	Drugs 1 Glucosamine Dimethyl fumarate SC-236	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols NOP2 and PVT1	Name 1 NOP2 nucleolar protein	Name2 Pvt1 oncogene	Pathway 1 rRNA modification in the nucleus and cytosol TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols AKT2 and FSHR	Name 1 AKT serine/threonine kinase 2	Name2 follicle stimulating hormone receptor	Pathway 1 Activation of BAD and translocation to mitochondria PIP3 activates AKT signaling PIP3 activates AKT signaling Downregulation of ERBB2:ERBB3 signaling Translocation of SLC2A4 (GLUT4) to the plasma membrane Activation of AKT2 PDE3B signalling Inhibition of TSC complex formation by PKB AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the nucleus Negative regulation of the PI3K/AKT network AKT-mediated inactivation of FOXO1A Deactivation of the beta-catenin transactivating complex CD28 dependent PI3K/Akt signaling Co-inhibition by CTLA4 G beta:gamma signalling through PI3Kgamma VEGFR2 mediated vascular permeability TP53 Regulates Metabolic Genes Constitutive Signaling by AKT1 E17K in Cancer Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Cyclin E associated events during G1/S transition Cyclin A:Cdk2-associated events at S phase entry RAB GEFs exchange GTP for GDP on RABs RUNX2 regulates genes involved in cell migration Regulation of PTEN stability and activity FLT3 Signaling Regulation of localization of FOXO transcription factors Estrogen-dependent nuclear events downstream of ESR-membrane signaling KEAP1-NFE2L2 pathway SARS-CoV-2 targets host intracellular signalling and regulatory pathways Regulation of MITF-M-dependent genes involved in pigmentation	Pathway 2 Hormone ligand-binding receptors G alpha (s) signalling events	Drugs 1 N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE	Drugs 2 Menotropins Follitropin Urofollitropin Choriogonadotropin alfa Suramin Corifollitropin alfa	Diseases 1 Ovarian cancer Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy	Diseases 2 Ovarian hyperstimulation syndrome (OHSS) Premature ovarian failure 46,XX disorders of sex development (Disorders of gonadal development), including: Ovotesticular DSD; Testicular DSD; Ovarian dysgenesis
Novel Novel	Symbols AKT2 and CHUK	Name 1 AKT serine/threonine kinase 2	Name2 component of inhibitor of nuclear factor kappa B kinase complex	Pathway 1 Activation of BAD and translocation to mitochondria PIP3 activates AKT signaling PIP3 activates AKT signaling Downregulation of ERBB2:ERBB3 signaling Translocation of SLC2A4 (GLUT4) to the plasma membrane Activation of AKT2 PDE3B signalling Inhibition of TSC complex formation by PKB AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the nucleus Negative regulation of the PI3K/AKT network AKT-mediated inactivation of FOXO1A Deactivation of the beta-catenin transactivating complex CD28 dependent PI3K/Akt signaling Co-inhibition by CTLA4 G beta:gamma signalling through PI3Kgamma VEGFR2 mediated vascular permeability TP53 Regulates Metabolic Genes Constitutive Signaling by AKT1 E17K in Cancer Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Cyclin E associated events during G1/S transition Cyclin A:Cdk2-associated events at S phase entry RAB GEFs exchange GTP for GDP on RABs RUNX2 regulates genes involved in cell migration Regulation of PTEN stability and activity FLT3 Signaling Regulation of localization of FOXO transcription factors Estrogen-dependent nuclear events downstream of ESR-membrane signaling KEAP1-NFE2L2 pathway SARS-CoV-2 targets host intracellular signalling and regulatory pathways Regulation of MITF-M-dependent genes involved in pigmentation	Pathway 2 Activation of NF-kappaB in B cells Activation of NF-kappaB in B cells ER-Phagosome pathway NOD1/2 Signaling Pathway TICAM1, RIP1-mediated IKK complex recruitment RIP-mediated NFkB activation via ZBP1 AKT phosphorylates targets in the cytosol Downstream TCR signaling FCERI mediated NF-kB activation TAK1-dependent IKK and NF-kappa-B activation Regulation of TNFR1 signaling TNFR1-induced NF-kappa-B signaling pathway IKBKB deficiency causes SCID IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) IkBA variant leads to EDA-ID Dectin-1 mediated noncanonical NF-kB signaling CLEC7A (Dectin-1) signaling Constitutive Signaling by AKT1 E17K in Cancer NIK-->noncanonical NF-kB signaling MAP3K8 (TPL2)-dependent MAPK1/3 activation Interleukin-1 signaling TRAF6 mediated NF-kB activation NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 IRAK1 recruits IKK complex IKK complex recruitment mediated by RIP1 SARS-CoV-2 activates/modulates innate and adaptive immune responses IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation Regulation of NF-kappa B signaling PKR-mediated signaling SLC15A4:TASL-dependent IRF5 activation Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells Modulation of host responses by IFN-stimulated genes	Drugs 1 N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE	Drugs 2 Aminosalicylic acid Mesalazine Acetylcysteine	Diseases 1 Ovarian cancer Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy	Diseases 2 Cocoon syndrome
Novel Novel	Symbols AKT2 and AKT1S1	Name 1 AKT serine/threonine kinase 2	Name2 AKT1 substrate 1	Pathway 1 Activation of BAD and translocation to mitochondria PIP3 activates AKT signaling PIP3 activates AKT signaling Downregulation of ERBB2:ERBB3 signaling Translocation of SLC2A4 (GLUT4) to the plasma membrane Activation of AKT2 PDE3B signalling Inhibition of TSC complex formation by PKB AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the nucleus Negative regulation of the PI3K/AKT network AKT-mediated inactivation of FOXO1A Deactivation of the beta-catenin transactivating complex CD28 dependent PI3K/Akt signaling Co-inhibition by CTLA4 G beta:gamma signalling through PI3Kgamma VEGFR2 mediated vascular permeability TP53 Regulates Metabolic Genes Constitutive Signaling by AKT1 E17K in Cancer Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Cyclin E associated events during G1/S transition Cyclin A:Cdk2-associated events at S phase entry RAB GEFs exchange GTP for GDP on RABs RUNX2 regulates genes involved in cell migration Regulation of PTEN stability and activity FLT3 Signaling Regulation of localization of FOXO transcription factors Estrogen-dependent nuclear events downstream of ESR-membrane signaling KEAP1-NFE2L2 pathway SARS-CoV-2 targets host intracellular signalling and regulatory pathways Regulation of MITF-M-dependent genes involved in pigmentation	Pathway 2 MTOR signalling mTORC1-mediated signalling AKT phosphorylates targets in the cytosol HSF1-dependent transactivation Constitutive Signaling by AKT1 E17K in Cancer	Drugs 1 N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE	Drugs 2	Diseases 1 Ovarian cancer Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy	Diseases 2
Novel Novel	Symbols ETS2 and POU5F1	Name 1 ETS proto-oncogene 2, transcription factor	Name2 POU class 5 homeobox 1	Pathway 1 Oncogene Induced Senescence	Pathway 2 POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation Transcriptional regulation of pluripotent stem cells Germ layer formation at gastrulation Formation of the anterior neural plate Specification of primordial germ cells Specification of the neural plate border	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols ETS2 and TDP2	Name 1 ETS proto-oncogene 2, transcription factor	Name2 tyrosyl-DNA phosphodiesterase 2	Pathway 1 Oncogene Induced Senescence	Pathway 2 Nonhomologous End-Joining (NHEJ)	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols NRAS and PLCE1	Name 1 NRAS proto-oncogene, GTPase	Name2 phospholipase C epsilon 1	Pathway 1 SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease Regulation of RAS by GAPs RAF activation RAF/MAP kinase cascade MAP2K and MAPK activation Negative regulation of MAPK pathway Neutrophil degranulation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions RAS signaling downstream of NF1 loss-of-function variants Paradoxical activation of RAF signaling by kinase inactive BRAF Insulin receptor signalling cascade PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAS signaling Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Estrogen-stimulated signaling through PRKCZ RAS processing Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Signaling by RAS GAP mutants Signaling by RAS GTPase mutants	Pathway 2 Synthesis of IP3 and IP4 in the cytosol	Drugs 1	Drugs 2	Diseases 1 Adrenal carcinoma Acute myeloid leukemia (AML) Oral cancer Multiple myeloma Malignant melanoma Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Hepatocellular carcinoma Thyroid cancer Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS	Diseases 2 Nephrotic syndrome and focal segmental glomerulosclerosis
Novel Novel	Symbols NRAS and MAPKAP1	Name 1 NRAS proto-oncogene, GTPase	Name2 MAPK associated protein 1	Pathway 1 SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease Regulation of RAS by GAPs RAF activation RAF/MAP kinase cascade MAP2K and MAPK activation Negative regulation of MAPK pathway Neutrophil degranulation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions RAS signaling downstream of NF1 loss-of-function variants Paradoxical activation of RAF signaling by kinase inactive BRAF Insulin receptor signalling cascade PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAS signaling Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Estrogen-stimulated signaling through PRKCZ RAS processing Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Signaling by RAS GAP mutants Signaling by RAS GTPase mutants	Pathway 2 PIP3 activates AKT signaling CD28 dependent PI3K/Akt signaling VEGFR2 mediated vascular permeability Constitutive Signaling by AKT1 E17K in Cancer Regulation of TP53 Degradation High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	Drugs 1	Drugs 2	Diseases 1 Adrenal carcinoma Acute myeloid leukemia (AML) Oral cancer Multiple myeloma Malignant melanoma Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Hepatocellular carcinoma Thyroid cancer Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS	Diseases 2
Novel	Symbols SNCA and LIN7C	Name 1 synuclein alpha	Name2 lin-7 cell polarity scaffold C	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Dopamine Neurotransmitter Release Cycle Neurexins and neuroligins Assembly and cell surface presentation of NMDA receptors	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel	Symbols SNCA and LRFN2	Name 1 synuclein alpha	Name2 leucine rich repeat and fibronectin type III domain containing 2	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Synaptic adhesion-like molecules	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel	Symbols SNCA and OSBPL7	Name 1 synuclein alpha	Name2 oxysterol binding protein like 7	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Synthesis of bile acids and bile salts	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel	Symbols SNCA and PSD3	Name 1 synuclein alpha	Name2 pleckstrin and Sec7 domain containing 3	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel	Symbols SNCA and RUFY1	Name 1 synuclein alpha	Name2 RUN and FYVE domain containing 1	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Synthesis of PIPs at the plasma membrane	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel	Symbols SNCA and SNX16	Name 1 synuclein alpha	Name2 sorting nexin 16	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel	Symbols SNCA and TRPV6	Name 1 synuclein alpha	Name2 transient receptor potential cation channel subfamily V member 6	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 TRP channels	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel	Symbols SNCA and TH	Name 1 synuclein alpha	Name2 tyrosine hydroxylase	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Catecholamine biosynthesis	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2 Phenylalanine Tyrosine Sapropterin Metyrosine 3-Tyrosine L-erythro-7,8-dihydrobiopterin	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2 Primary torsion dystonia (PTD)
Novel	Symbols EPB41L1 and STARD13	Name 1 erythrocyte membrane protein band 4.1 like 1	Name2 StAR related lipid transfer domain containing 13	Pathway 1 Trafficking of AMPA receptors Neurexins and neuroligins Sensory processing of sound by inner hair cells of the cochlea Sensory processing of sound by outer hair cells of the cochlea	Pathway 2 RHOA GTPase cycle RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols EPB41L1 and GRIA1	Name 1 erythrocyte membrane protein band 4.1 like 1	Name2 glutamate ionotropic receptor AMPA type subunit 1	Pathway 1 Trafficking of AMPA receptors Neurexins and neuroligins Sensory processing of sound by inner hair cells of the cochlea Sensory processing of sound by outer hair cells of the cochlea	Pathway 2 COPII-mediated vesicle transport Activation of AMPA receptors Trafficking of AMPA receptors Trafficking of GluR2-containing AMPA receptors Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Cargo concentration in the ER Synaptic adhesion-like molecules Long-term potentiation	Drugs 1	Drugs 2 Glutamic acid Butabarbital Lamotrigine Isoflurane Ethanol Methoxyflurane Desflurane Sevoflurane Talampanel CX-717 CX516 Perampanel Tianeptine Fluciclovine (18F)	Diseases 1	Diseases 2
Novel	Symbols RELA and UNC5CL	Name 1 RELA proto-oncogene, NF-kB subunit	Name2 unc-5 family C-terminal like	Pathway 1 Activation of NF-kappaB in B cells RIP-mediated NFkB activation via ZBP1 Regulated proteolysis of p75NTR Downstream TCR signaling NF-kB is activated and signals survival Senescence-Associated Secretory Phenotype (SASP) FCERI mediated NF-kB activation DEx/H-box helicases activate type I IFN and inflammatory cytokines production PKMTs methylate histone lysines Transcriptional regulation of white adipocyte differentiation TAK1-dependent IKK and NF-kappa-B activation Interleukin-1 processing SUMOylation of immune response proteins IkBA variant leads to EDA-ID Dectin-1 mediated noncanonical NF-kB signaling CLEC7A (Dectin-1) signaling CD209 (DC-SIGN) signaling CLEC7A/inflammasome pathway The NLRP3 inflammasome Transcriptional Regulation by VENTX Interleukin-1 signaling TRAF6 mediated NF-kB activation Purinergic signaling in leishmaniasis infection SARS-CoV-1 activates/modulates innate immune responses Regulation of NFE2L2 gene expression Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells Regulation of PD-L1(CD274) transcription	Pathway 2	Drugs 1 Glucosamine Dimethyl fumarate SC-236	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols RELA and UBE2C	Name 1 RELA proto-oncogene, NF-kB subunit	Name2 ubiquitin conjugating enzyme E2 C	Pathway 1 Activation of NF-kappaB in B cells RIP-mediated NFkB activation via ZBP1 Regulated proteolysis of p75NTR Downstream TCR signaling NF-kB is activated and signals survival Senescence-Associated Secretory Phenotype (SASP) FCERI mediated NF-kB activation DEx/H-box helicases activate type I IFN and inflammatory cytokines production PKMTs methylate histone lysines Transcriptional regulation of white adipocyte differentiation TAK1-dependent IKK and NF-kappa-B activation Interleukin-1 processing SUMOylation of immune response proteins IkBA variant leads to EDA-ID Dectin-1 mediated noncanonical NF-kB signaling CLEC7A (Dectin-1) signaling CD209 (DC-SIGN) signaling CLEC7A/inflammasome pathway The NLRP3 inflammasome Transcriptional Regulation by VENTX Interleukin-1 signaling TRAF6 mediated NF-kB activation Purinergic signaling in leishmaniasis infection SARS-CoV-1 activates/modulates innate immune responses Regulation of NFE2L2 gene expression Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells Regulation of PD-L1(CD274) transcription	Pathway 2 Inactivation of APC/C via direct inhibition of the APC/C complex APC/C:Cdc20 mediated degradation of Cyclin B Autodegradation of Cdh1 by Cdh1:APC/C APC/C:Cdc20 mediated degradation of Securin APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 Cdc20:Phospho-APC/C mediated degradation of Cyclin A Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase Regulation of APC/C activators between G1/S and early anaphase APC/C:Cdc20 mediated degradation of mitotic proteins Phosphorylation of the APC/C APC-Cdc20 mediated degradation of Nek2A Separation of Sister Chromatids Senescence-Associated Secretory Phenotype (SASP) Assembly of the pre-replicative complex CDK-mediated phosphorylation and removal of Cdc6 Transcriptional Regulation by VENTX Synthesis of active ubiquitin: roles of E1 and E2 enzymes Aberrant regulation of mitotic exit in cancer due to RB1 defects Antigen processing: Ubiquitination & Proteasome degradation	Drugs 1 Glucosamine Dimethyl fumarate SC-236	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols NOP2 and PVT1	Name 1 NOP2 nucleolar protein	Name2 Pvt1 oncogene	Pathway 1 rRNA modification in the nucleus and cytosol TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols AKT2 and FSHR	Name 1 AKT serine/threonine kinase 2	Name2 follicle stimulating hormone receptor	Pathway 1 Activation of BAD and translocation to mitochondria PIP3 activates AKT signaling PIP3 activates AKT signaling Downregulation of ERBB2:ERBB3 signaling Translocation of SLC2A4 (GLUT4) to the plasma membrane Activation of AKT2 PDE3B signalling Inhibition of TSC complex formation by PKB AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the nucleus Negative regulation of the PI3K/AKT network AKT-mediated inactivation of FOXO1A Deactivation of the beta-catenin transactivating complex CD28 dependent PI3K/Akt signaling Co-inhibition by CTLA4 G beta:gamma signalling through PI3Kgamma VEGFR2 mediated vascular permeability TP53 Regulates Metabolic Genes Constitutive Signaling by AKT1 E17K in Cancer Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Cyclin E associated events during G1/S transition Cyclin A:Cdk2-associated events at S phase entry RAB GEFs exchange GTP for GDP on RABs RUNX2 regulates genes involved in cell migration Regulation of PTEN stability and activity FLT3 Signaling Regulation of localization of FOXO transcription factors Estrogen-dependent nuclear events downstream of ESR-membrane signaling KEAP1-NFE2L2 pathway SARS-CoV-2 targets host intracellular signalling and regulatory pathways Regulation of MITF-M-dependent genes involved in pigmentation	Pathway 2 Hormone ligand-binding receptors G alpha (s) signalling events	Drugs 1 N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE	Drugs 2 Menotropins Follitropin Urofollitropin Choriogonadotropin alfa Suramin Corifollitropin alfa	Diseases 1 Ovarian cancer Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy	Diseases 2 Ovarian hyperstimulation syndrome (OHSS) Premature ovarian failure 46,XX disorders of sex development (Disorders of gonadal development), including: Ovotesticular DSD; Testicular DSD; Ovarian dysgenesis
Novel	Symbols AKT2 and CHUK	Name 1 AKT serine/threonine kinase 2	Name2 component of inhibitor of nuclear factor kappa B kinase complex	Pathway 1 Activation of BAD and translocation to mitochondria PIP3 activates AKT signaling PIP3 activates AKT signaling Downregulation of ERBB2:ERBB3 signaling Translocation of SLC2A4 (GLUT4) to the plasma membrane Activation of AKT2 PDE3B signalling Inhibition of TSC complex formation by PKB AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the nucleus Negative regulation of the PI3K/AKT network AKT-mediated inactivation of FOXO1A Deactivation of the beta-catenin transactivating complex CD28 dependent PI3K/Akt signaling Co-inhibition by CTLA4 G beta:gamma signalling through PI3Kgamma VEGFR2 mediated vascular permeability TP53 Regulates Metabolic Genes Constitutive Signaling by AKT1 E17K in Cancer Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Cyclin E associated events during G1/S transition Cyclin A:Cdk2-associated events at S phase entry RAB GEFs exchange GTP for GDP on RABs RUNX2 regulates genes involved in cell migration Regulation of PTEN stability and activity FLT3 Signaling Regulation of localization of FOXO transcription factors Estrogen-dependent nuclear events downstream of ESR-membrane signaling KEAP1-NFE2L2 pathway SARS-CoV-2 targets host intracellular signalling and regulatory pathways Regulation of MITF-M-dependent genes involved in pigmentation	Pathway 2 Activation of NF-kappaB in B cells Activation of NF-kappaB in B cells ER-Phagosome pathway NOD1/2 Signaling Pathway TICAM1, RIP1-mediated IKK complex recruitment RIP-mediated NFkB activation via ZBP1 AKT phosphorylates targets in the cytosol Downstream TCR signaling FCERI mediated NF-kB activation TAK1-dependent IKK and NF-kappa-B activation Regulation of TNFR1 signaling TNFR1-induced NF-kappa-B signaling pathway IKBKB deficiency causes SCID IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) IkBA variant leads to EDA-ID Dectin-1 mediated noncanonical NF-kB signaling CLEC7A (Dectin-1) signaling Constitutive Signaling by AKT1 E17K in Cancer NIK-->noncanonical NF-kB signaling MAP3K8 (TPL2)-dependent MAPK1/3 activation Interleukin-1 signaling TRAF6 mediated NF-kB activation NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 IRAK1 recruits IKK complex IKK complex recruitment mediated by RIP1 SARS-CoV-2 activates/modulates innate and adaptive immune responses IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation Regulation of NF-kappa B signaling PKR-mediated signaling SLC15A4:TASL-dependent IRF5 activation Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells Modulation of host responses by IFN-stimulated genes	Drugs 1 N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE	Drugs 2 Aminosalicylic acid Mesalazine Acetylcysteine	Diseases 1 Ovarian cancer Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy	Diseases 2 Cocoon syndrome
Novel	Symbols AKT2 and AKT1S1	Name 1 AKT serine/threonine kinase 2	Name2 AKT1 substrate 1	Pathway 1 Activation of BAD and translocation to mitochondria PIP3 activates AKT signaling PIP3 activates AKT signaling Downregulation of ERBB2:ERBB3 signaling Translocation of SLC2A4 (GLUT4) to the plasma membrane Activation of AKT2 PDE3B signalling Inhibition of TSC complex formation by PKB AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the nucleus Negative regulation of the PI3K/AKT network AKT-mediated inactivation of FOXO1A Deactivation of the beta-catenin transactivating complex CD28 dependent PI3K/Akt signaling Co-inhibition by CTLA4 G beta:gamma signalling through PI3Kgamma VEGFR2 mediated vascular permeability TP53 Regulates Metabolic Genes Constitutive Signaling by AKT1 E17K in Cancer Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Cyclin E associated events during G1/S transition Cyclin A:Cdk2-associated events at S phase entry RAB GEFs exchange GTP for GDP on RABs RUNX2 regulates genes involved in cell migration Regulation of PTEN stability and activity FLT3 Signaling Regulation of localization of FOXO transcription factors Estrogen-dependent nuclear events downstream of ESR-membrane signaling KEAP1-NFE2L2 pathway SARS-CoV-2 targets host intracellular signalling and regulatory pathways Regulation of MITF-M-dependent genes involved in pigmentation	Pathway 2 MTOR signalling mTORC1-mediated signalling AKT phosphorylates targets in the cytosol HSF1-dependent transactivation Constitutive Signaling by AKT1 E17K in Cancer	Drugs 1 N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE	Drugs 2	Diseases 1 Ovarian cancer Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy	Diseases 2
Novel	Symbols ETS2 and POU5F1	Name 1 ETS proto-oncogene 2, transcription factor	Name2 POU class 5 homeobox 1	Pathway 1 Oncogene Induced Senescence	Pathway 2 POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation Transcriptional regulation of pluripotent stem cells Germ layer formation at gastrulation Formation of the anterior neural plate Specification of primordial germ cells Specification of the neural plate border	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols ETS2 and TDP2	Name 1 ETS proto-oncogene 2, transcription factor	Name2 tyrosyl-DNA phosphodiesterase 2	Pathway 1 Oncogene Induced Senescence	Pathway 2 Nonhomologous End-Joining (NHEJ)	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols NRAS and PLCE1	Name 1 NRAS proto-oncogene, GTPase	Name2 phospholipase C epsilon 1	Pathway 1 SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease Regulation of RAS by GAPs RAF activation RAF/MAP kinase cascade MAP2K and MAPK activation Negative regulation of MAPK pathway Neutrophil degranulation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions RAS signaling downstream of NF1 loss-of-function variants Paradoxical activation of RAF signaling by kinase inactive BRAF Insulin receptor signalling cascade PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAS signaling Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Estrogen-stimulated signaling through PRKCZ RAS processing Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Signaling by RAS GAP mutants Signaling by RAS GTPase mutants	Pathway 2 Synthesis of IP3 and IP4 in the cytosol	Drugs 1	Drugs 2	Diseases 1 Adrenal carcinoma Acute myeloid leukemia (AML) Oral cancer Multiple myeloma Malignant melanoma Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Hepatocellular carcinoma Thyroid cancer Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS	Diseases 2 Nephrotic syndrome and focal segmental glomerulosclerosis
Novel	Symbols NRAS and MAPKAP1	Name 1 NRAS proto-oncogene, GTPase	Name2 MAPK associated protein 1	Pathway 1 SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease Regulation of RAS by GAPs RAF activation RAF/MAP kinase cascade MAP2K and MAPK activation Negative regulation of MAPK pathway Neutrophil degranulation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions RAS signaling downstream of NF1 loss-of-function variants Paradoxical activation of RAF signaling by kinase inactive BRAF Insulin receptor signalling cascade PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAS signaling Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Estrogen-stimulated signaling through PRKCZ RAS processing Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Signaling by RAS GAP mutants Signaling by RAS GTPase mutants	Pathway 2 PIP3 activates AKT signaling CD28 dependent PI3K/Akt signaling VEGFR2 mediated vascular permeability Constitutive Signaling by AKT1 E17K in Cancer Regulation of TP53 Degradation High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	Drugs 1	Drugs 2	Diseases 1 Adrenal carcinoma Acute myeloid leukemia (AML) Oral cancer Multiple myeloma Malignant melanoma Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Hepatocellular carcinoma Thyroid cancer Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS	Diseases 2

Page 41 out of 98 pages

Search Results : Cancer